Sanofi SA (SAN) Given a €96.00 Price Target by Deutsche Bank AG Analysts

Deutsche Bank AG set a €96.00 ($111.63) price target on Sanofi SA (EPA:SAN) in a research report released on Wednesday, October 18th. The brokerage currently has a buy rating on the stock.

A number of other brokerages have also recently commented on SAN. HSBC Holdings plc set a €81.00 ($94.19) target price on Sanofi SA and gave the company a neutral rating in a report on Wednesday, August 30th. J P Morgan Chase & Co set a €95.00 ($110.47) target price on Sanofi SA and gave the company a neutral rating in a report on Thursday, June 22nd. Jefferies Group LLC set a €87.00 ($101.16) target price on Sanofi SA and gave the company a neutral rating in a report on Thursday, August 24th. Goldman Sachs Group, Inc. (The) set a €82.00 ($95.35) target price on Sanofi SA and gave the company a neutral rating in a report on Monday, August 7th. Finally, Kepler Capital Markets set a €89.00 ($103.49) target price on Sanofi SA and gave the company a buy rating in a report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have given a buy rating to the stock. Sanofi SA has an average rating of Hold and an average target price of €87.24 ($101.44).

Shares of Sanofi SA (SAN) traded up €0.58 ($0.67) during midday trading on Wednesday, hitting €79.60 ($92.56). 1,790,000 shares of the stock traded hands, compared to its average volume of 1,840,000. Sanofi SA has a one year low of €70.94 ($82.49) and a one year high of €92.97 ($108.10).

COPYRIGHT VIOLATION NOTICE: This story was first posted by BBNS and is owned by of BBNS. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://baseballnewssource.com/markets/deutsche-bank-ag-analysts-give-sanofi-sa-san-a-96-00-price-target/1722462.html.

Sanofi SA Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.